Evidence map›Paper›PMID 38747525›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort.

Marc D Rudolph, Courtney L Sutphen, Thomas C Register, Christopher T Whitlow, Kiran K Solingapuram Sai, Timothy M Hughes, James R Bateman, Jeffrey L Dage, Kristen A Russ, Michelle M Mielke and 2 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  18. Plasma NfL and GFAP for predicting VCI and related brain changes in community and clinical cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marc D RudolphDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0001-7046-1169
Courtney L SutphenDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Thomas C RegisterDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Christopher T WhitlowDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Kiran K Solingapuram SaiDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Timothy M HughesDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
James R BatemanDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Jeffrey L DageDepartment Of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Kristen A RussDepartment Of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Michelle M MielkeDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Suzanne CraftDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Samuel N LockhartDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
The IU/JAX Alzheimer's Disease Precision Models Center: Rat F344U54AG054345 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Gregory W Carter, Gareth R Howell · 2016 to 2026
$95.6M
ADRC Consortium for Clarity in ADRD Research Through ImagingU01AG082350 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sarah Biber, BRADFORD C DICKERSON · 2023 to 2026
$90.0M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Structural Biology CoreU54AG065181 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Bruce T Lamb, Alan D. Palkowitz · 2019 to 2026
$61.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Research Education ComponentP30AG072976 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI ANDREW J SAYKIN · 2021 to 2026
$24.1M
Epidemiological and Genetic Investigations of Blood-Based Biomarkers for Alzheimer's Disease in the Multiethnic, Washington Heights, Inwood, Columbia Aging Project (WHICAP)R01AG072474 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BRICKMAN, ADAM M, MANLY, JENNIFER JAIE · 2021 to 2025
$13.3M
Michael J Fox Foundation MJFF-023365NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072976NIA NIH HHS R01 AG054069NIA NIH HHS R01 AG058969NIA NIH HHS R01 AG068193NIA NIH HHS R01 AG072474NIA NIH HHS R01 AG077202NIA NIH HHS T32 AG033534NIA NIH HHS U01 AG057195NIA NIH HHS U01 AG082350NIA NIH HHS U19 AG074879NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG072122NIA NIH HHS U24 AG082930NIA NIH HHS U54 AG054345NIA NIH HHS U54 AG065181NIH HHS P30AG049638NIH HHS P30AG072947NIH HHS P30AG072976NIH HHS R01AG068193NIH HHS R01AG072474NIH HHS R01AG077202NIH HHS RD005665NIH HHS RD006263NIH HHS T32AG033534NIH HHS U01AG057195NIH HHS U01AG082350NIH HHS U19AG074879NIH HHS U24AG021886NIH HHS U24AG082930NIH HHS U54AG054345NIH HHS U54AG065181
6 · The paper itself

Abstract

introductionWe evaluated associations between plasma and neuroimaging-derived biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities.

methodsWe examined plasma biomarkers (neurofilament light chain, glial fibrillary acidic protein, amyloid beta [Aβ] 42/40, phosphorylated tau 181) and neuroimaging measures of amyloid deposition (Aβ-positron emission tomography [PET]), total brain volume, white matter hyperintensity volume, diffusion-weighted fractional anisotropy, and neurite orientation dispersion and density imaging free water. Participants were adjudicated as cognitively unimpaired (CU; N = 299), mild cognitive impairment (MCI; N = 192), or dementia (DEM; N = 65). Biomarkers were compared across groups stratified by diagnosis, sex, race, and APOE ε4 carrier status. General linear models examined plasma-imaging associations before and after adjusting for demographics (age, sex, race, education), APOE ε4 status, medications, diagnosis, and other factors (estimated glomerular filtration rate [eGFR], body mass index [BMI]).

resultsPlasma biomarkers differed across diagnostic groups (DEM > MCI > CU), were altered in Aβ-PET-positive individuals, and were associated with poorer brain health and kidney function. DISCUSSION: eGFR and BMI did not substantially impact associations between plasma and neuroimaging biomarkers. HIGHLIGHTS: Plasma biomarkers differ across diagnostic groups (DEM > MCI > CU) and are altered in Aβ-PET-positive individuals. Altered plasma biomarker levels are associated with poorer brain health and kidney function. Plasma and neuroimaging biomarker associations are largely independent of comorbidities.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersMagnetic Resonance ImagingPositron-Emission TomographyAgedBrainCognitive DysfunctionCohort StudiesComorbidityDementiaFemaleHumansIndependent LivingMaleMiddle AgedAmyloid beta-PeptidesBiomarkerstau Proteinsdementiasneuroimagingplasma biomarkers

Identifiers

PMID38747525
PMCPMC11180870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.